AbCellera, a Vancouver, BC, Canada-based developer of next-generation therapeutic antibodies, closed its $10m Series A financing.
The round was led by DCVC Bio. In connection with the investment, John Hamer, Managing Partner at DCVC Bio, joined AbCellera’s Board of Directors, along with AbCellera Co-Founder Véronique Lecault. Doug Janzen will be stepping down from his role as Chairman of the Board.
The company intends to use the funds to accelerate the growth of its therapeutic antibody discovery business, including investments to build capacity and integration of advanced technological capabilities spanning computation, protein engineering, and immune repertoire profiling.
Founded in 2012 based on microfluidic single-cell technology developed at the University of British Columbia and led by Carl Hansen, CEO, AbCellera is advancing a single-cell platform that integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation.
The company applies machine learning algorithms and custom data visualization tools to optimize lead selection, accelerate discovery, and uncover targets for a wide range of therapeutic modalities.